IMPAX

pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations and substances for the treatment of inflammation, musculoskeletal, respiratory, and immune system related diseases and disorders; pharmaceutical preparations for use in treating cancer; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, and psychiatric diseases and disorders; pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the prevention, treatment and/or alleviation of rheumatoid arthritis and of all diseases and disorders related to rheumatoid arthritis; pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders